Fecal immunochemical tests (FITs) for hemoglobin (Hb) are increasingly used for colorectal cancer (CRC) screening. We aimed to review, summarize and compare reported diagnostic performance of various FITs. PubMed and Web of Science were searched from inception to July 24, 2017. Data on diagnostic performance of quantitative FITs, conducted in colonoscopycontrolled average-risk screening populations, were extracted. Summary receiver operating characteristic (ROC) curves were plotted and correlations between thresholds, positivity rates (PRs), sensitivities and specificities were assessed. Seven test brands were investigated across 22 studies. Although reported sensitivities for CRC, advanced adenoma (AA) and any advanced neoplasm (AN) varied widely (ranges: 25-100%, 6-44% and 9-60%, respectively), with specificities for AN ranging from 82% to 99%, the estimates were very close to the respective summary ROC curves whose areas under the curve (95% CI) were 0.905 (0.88-0.94), 0.683 (0.67-0.70) and 0.710 (0.70-0.72) for CRC, AA and AN, respectively. The seemingly large heterogeneity essentially reflected variations in test thresholds (range: 2-82 mg Hb/g feces) and showed moderate correlations with sensitivity (r 5 20.49) and specificity (r 5 0.60) for AN. By contrast, observed PRs (range: 1-21%) almost perfectly correlated with sensitivity (r 5 0.84) and specificity (r 5 20.94) for AN. The apparent large heterogeneity in diagnostic performance between various FITs can be almost completely overcome by appropriate threshold adjustments. Instead of simply applying the threshold recommended by the manufacturer, screening programs should adjust the threshold to yield a desired PR which is a very good proxy indicator for the specificity and the subsequent colonoscopy workload.
Introduction
With approximately 1.4 million new diagnoses and 700,000 deaths per year, colorectal cancer (CRC) is the third most common cancer globally. 1 Several randomized trials have demonstrated that CRC incidence and mortality can be reduced by annual or biennial screening with fecal occult blood tests (FOBTs). [2] [3] [4] While these effects have been achieved with traditional, guaiac-based FOBTs requiring stool sampling on multiple consecutive days, even larger effects might be expected with newer fecal immunochemical tests (FITs) for hemoglobin (Hb), which have been shown to have substantially higher sensitivities for detecting CRC and its precursors even with only one single fecal sample. [5] [6] [7] Further advantages of FITs over guaiac-based FOBTs include more convenient stool sampling and simpler applicability without dietary restrictions which go along with enhanced adherence in population-based screening. 8, 9 Therefore, FITs are increasingly recommended 10, 11 and used 12 for CRC screening. With the perspective of a new large market for CRC screening, multiple companies have developed their own FITs, and the question arises to what extent they are comparable with respect to diagnostic performance and other key factors. Previous studies have demonstrated large differences in the diagnostic performance of qualitative FITs, with some of them showing very high sensitivity at very low specificity and vice versa, 13 which probably mostly reflect differences in the thresholds for test positivity.
14 With quantitative FITs, automated quantification of fecal Hb concentrations under quality controlled laboratory conditions and adjustments of thresholds to best serve specific screening programs are possible. 15 However, even for quantitative FITs, major differences in diagnostic performance have been reported, even at comparable threshold values, [16] [17] [18] but the extent and potential reasons for such heterogeneity have not been systematically explored.
We performed a systematic literature review and metaanalysis to evaluate and compare the diagnostic performance of quantitative FITs for Hb at several threshold values and to assess the potential influence of various factors on test performance.
Methods

Data sources and searches
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 19 We searched the electronic database of PubMed and Web of Science for eligible studies from inception to July 24, 2017 with the following search term combination: ("fecal immunochemical test" OR FIT OR fecal OR immunochemical OR "fecal occult blood test" OR "occult blood test" OR FOBT OR iFOBT OR "stool test") AND (endoscopy OR colonoscopy OR sigmoidoscopy OR diagnosis OR diagnostic OR screen OR screening) AND ("colorectal neoplasm" OR "colon neoplasm" OR "colonic neoplasm" OR "rectal neoplasm" OR "colorectal cancer" OR "colon cancer" OR "colonic cancer" OR CRC OR "colorectal tumor" OR "colon tumor" OR "colonic tumor" OR adenoma OR "colorectal polyp" OR "colon polyp" OR "colonic polyp") AND (sensitivity OR specificity OR accuracy OR performance). We also scanned reference lists of related articles, reports, guidelines, presentations, comments and of all full-text articles, which were assessed for eligibility. Furthermore, we contacted five corresponding authors of seven articles [20] [21] [22] [23] [24] [25] [26] and two companies (Eiken Chemical, Tokyo, Japan and R-Biopharm, Darmstadt, Germany) to obtain additional information about their tests.
Study selection
Studies were considered to be eligible if they were conducted in an average-risk population, with screening colonoscopy as the reference test and sensitivities and specificities for CRC, advanced adenoma (AA) or any advanced neoplasm (AN), that is, CRC or AA, of a quantitative FIT were reported. The colonoscopy was required to be conducted independently of the quantitative FIT result (i.e., not only in case of positive tests) and the fecal samples had to be collected before starting the bowel lavage for colonoscopy. When the same quantitative FIT results from the same study population were published several times, we included only the test results of the earlier published article or of the larger study cohort. Full text articles were screened for eligibility by the first author and ambiguities were resolved by discussion among AG, MB, PSK and HB and by contacting the corresponding author of the article.
Data extraction and synthesis
Two reviewers (AG, MB) independently extracted data on authors, publication years, countries, study populations, preanalytics, test brands, thresholds and diagnostic performances. Any disagreements were resolved by consensus after discussion between the authors. If more than three thresholds were investigated, we included only the test results of the smallest, the largest and the median threshold value.
Additionally, nonreported sensitivities and specificities for CRC, AA and AN as well as positivity rates (PRs) were calculated using the numbers of true and false positives and negatives. Furthermore, we recomputed all sensitivities and specificities of every study with their corresponding 95% Clopper-Pearson confidence intervals (CIs). Thresholds expressed as nanogram of Hb per milliliter of buffer were converted to microgram of Hb per gram feces. 27 
Statistical analyses
We conducted a meta-analysis by plotting the summery receiver operating characteristic (ROC) curves for the detection of CRC, AA and AN, respectively, and computing its corresponding area under the curves (AUCs). 28 If more than one threshold value was investigated in a study, we included only the threshold result that was closest to the median and most frequently used specificity of 95%. Studies with <4 CRC cases were excluded from the summary ROC curve for the detection of CRC.
We furthermore conducted correlation analyses including all studies and all threshold results. We assessed correlations between (i) the threshold and the sensitivity and specificity for AN, respectively and between (ii) the PR and the sensitivity and specificity for AN, respectively. Spearman's rank correlation coefficients (r) and p-values were calculated.
All statistical tests were two-sided and p-values below 0.05 were considered to be statistically significant. The R language and environment for statistical computing was used for all statistical analyses. 29 The R package mada 30 was used to compute the 95% Clopper-Pearson CIs of the sensitivity and specificity values and to calculate the summary ROC curves with its AUCs.
Quality assessment
AG and MB independently assessed the risk of bias for each study by using the Quality Assessment of Diagnostic Accuracy Studies 2 instrument (QUADAS-2). 31 The QUADAS-2 tool was tailored to the specific review topic, before applying it. Any disagreements between initial ratings were resolved by consensus after discussion between the authors.
Results
Study selection
The search in PubMed and Web of Science resulted in 2,348 articles, of which 760 were excluded due to being duplicates (n 5 706) or not in English or German language (n 5 54) (Fig. 1 ). After screening of 1,588 articles for titles and abstracts, 161 articles were left for full text review. In total 22 articles 5, 6, [20] [21] [22] [23] [24] [25] [26] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] fulfilled the inclusion criteria and two 36, 37 of them were found via cross referencing. Of the four articles 5, 26, 38, 41 that have investigated the same FIT in an overlapping study cohort, we excluded three studies 26, 38, 41 from the meta-analysis. Furthermore, the study from Graser et al. 40 had to be excluded from the summary ROC curve for the detection of CRC, because of the inclusion of only one CRC patient.
In addition to the information provided by the 22 original articles, three study protocols, [44] [45] [46] a corrigendum from Park et al. 6 and supplementary material from Imperiale et al. 44 were considered. Authors of three articles 20, 25, 26 provided us additional data on the chosen thresholds and on the diagnostic performance. The two companies (Eiken Chemical and RBiopharm) provided us information about conducting their tests according to manufacturers' instructions. Table 1 gives an overview of the included 22 studies, sorted by the number of patients with CRC. Half of the studies were conducted in a Western population (Europe and North America) and the other half in an Asian population. The numbers of CRC patients ranged from 0 to 79, with only five studies including >20 CRC patients. The numbers of AA were on average 11 times larger, ranging from 0 to 757. The mean age ranged between 46 and 64 years and the proportion of males ranged from 38% to 85%.
Study characteristics
In the majority of the studies, AA was defined as adenoma with at least one of the following features: 1 cm in size, high-grade dysplasia or villous components. In three studies, 24, 36, 44 slightly different definitions or endpoints were used. Morikawa et al. 24 defined AA as adenoma with 1 cm in diameter or with high-grade dysplasia and for Nakazato et al. 36 the test performance was evaluated for large adenomas ( 1 cm in diameter) only, not all AAs. Imperiale et al. 44 on the other hand evaluated the test performance for advanced precancerous lesions, including AA and sessile serrated polyps measuring 1 cm in the greatest dimension.
Seven quantitative FIT brands from four manufacturers were evaluated. Four of the FIT brands (OC Sensor, OC Hemodia, OC Sensa micro and OC FIT-Chek) were provided by the same manufacturer Eiken Chemical (Tokyo, Japan). The three other FIT brands (Ridascreen Hb, FOB Gold and Magstream) were provided by R-Biopharm (Darmstadt, Germany), Sentinel Diagnostics (Milan, Italy) and Fujirebio (Tokyo, Japan), respectively. All of them were laboratorybased tests and only Brenner et al. 5, 26 have compared the diagnostic performance of two different FIT brands within the same study cohort.
Diagnostic performance
The sensitivities for CRC, AA and AN ranged from 25% to 100%, 6% to 44% and from 9% to 60%, respectively, with specificities for AN ranging from 82% to 99% (Table 2 ). The PRs ranged from 1% to 21% and the threshold values for positivity were between 2.0 and 82.1 mg Hb/g feces, while Liu et al. 23 did not report the threshold value. The AUCs for the detection of AN were provided in nine publications and ranged from 0.62 to 0.73. At the most frequently used threshold of 20 mg Hb/g feces, the sensitivities for CRC, AA and AN and the specificities for AN still showed large variation, ranging from 25% to 100%, 6% to 39%, 9% to 42% and from 84% to 99%, respectively, with PRs ranging from 1% to 19%. In contrast to that, at the most frequently observed PR of 5%, the estimates of diagnostic performance were much narrower, with sensitivities for CRC, AA and AN ranging from 60% to 87%, 16% to 24%, 17% to 39%, respectively, and almost identical specificities for AN (range: 96-98%), whereas the threshold values varied widely ranging from 6.1 to 82.1 mg Hb/g feces.
Summary ROC curve and AUC Figure 2 shows the sensitivity plotted against one minus specificity for each study (n 5 19), included in the meta-analysis as well as the summary ROC curve and the corresponding AUC for the detection of CRC, AA and AN, respectively. At a specificity of 95%, the sensitivity value, extracted from the respective summary ROC curve, was 73% for CRC, 25% for AA and 29% for AN and at a specificity of 90% the sensitivities for CRC, AA and AN were 78%, 34% and 39%, respectively. For the detection of AA and AN, the estimates of diagnostic performance were very close to the summary ROC curve, indicating the achievement of similar diagnostic performances with appropriate threshold adjustments among the different FIT brands. Due to much smaller numbers of CRC patients (compared to the numbers of AA patients) and different CRC stage distributions across the studies, the sensitivities for CRC showed larger variation around the summary ROC curve.
Correlation analyses
The majority of the included studies used the preset thresholds recommended by the manufacturers or a multiple of it, which showed only a moderate correlation with the sensitivity (r 5 20.49) and the specificity for AN (r 5 0.60), respectively (Figs. 3a and 3b ) as well as with the PR (r 5 20.55).
In contrast to that, the PR showed a very strong correlation with the sensitivity for AN (r 5 0.84) and an almost perfect negative association with the specificity for AN (r 5 20.94) (Figs. 3c and 3d ).
Quality assessment
The QUADAS-2 tool revealed that in the risk of bias section all high risk results occurred in the index test domain. The reasons were deviations in fecal collection method or sample storage condition from the manufacturers instructions (Supporting Information Table 1 and Fig. 1 ). In three studies, 35, 36, 40 more than one fecal sample was used for test evaluation, in seven studies 5, 20, 26, 37, 38, 40, 41 the fecal samples were not directly collected with a specific FSD and in two studies 39, 43 the fecal-filled FSDs were stored frozen. The applicability section showed that the greatest concerns came from the patient selection domain, where a proportion of participants that were preselected due to a family history of CRC 21, 34, 35, 39, 42 and/or a proportion of younger individuals (<50 years) [23] [24] [25] [34] [35] [36] [37] 41 were partly included in an averagerisk screening population.
Eight studies 5, 6, 20, 26, 32, 33, 38, 44 were rated of low risk results regarding all risk of bias and applicability domains.
Discussion
Our systematic review and meta-analysis of quantitative FITs conducted in average-risk screening populations underlines the excellent potential of FITs to detect most CRCs at high levels of specificity. Although reported diagnostic performance indicators of the tests varied widely, the sensitivity and specificity values were close to the summary ROC curve, indicating that this apparent large heterogeneity can be almost completely overcome by appropriate threshold adjustments. Most of the studies used the threshold value recommended by the manufactures which has only a modest correlation with the sensitivity and specificity. By contrast, the PR is a very good proxy indicator for the diagnostic performance. For example, when the same threshold value of 20 mg Hb/g feces was used in different screening settings around the world, the sensitivities, specificities and PRs varied widely, whereas a much narrower range of sensitivities and almost identical specificities (range: 96-98%) were observed with thresholds that have yielded the same PR (here: 5%).
Even though almost all test performance indicators were located close to the summary ROC curve, the large differences in study population, pre-analytical sample handing and the wide range of specificity values (82-99%) make a comparative evaluation of the different FIT brands difficult, if not impossible. Especially the sensitivities for CRC varied widely, probably owing to the relative small case numbers and the different CRC stage distributions across the different studies. Several previous studies showed higher sensitivities at advanced compared to earlier CRC stages. 6, 24, 26, 44 In addition, differences among the different FIT systems, like the use of different antibodies with different abilities to detect partly degraded Hb variants, the use of different preservative buffer systems and the use of different reading techniques make a comparative evaluation of different FITs across different studies even more difficult. 47 Furthermore, we could not include a variety of commonly used FIT brands due to lack of published evaluations meeting our inclusion criteria. Only two of the identified studies have compared the diagnostic performance of two quantitative FITs (OC Sensor and Ridascreen Hb) head-to-head within the same study population using identical fecal samples. 5, 26 They showed, that with appropriate threshold adjustments (yielding the same PR 5 or specificity 26 ), similar diagnostic performances between both tests were observed.
By contrast, two population-based studies conducted in Latvia and in the Netherlands observed significant differences in PRs between two different FIT brands (OC Sensor and FOB Gold), in spite of applying an identical threshold (10 mg Hb/g feces). 48, 49 Furthermore, even large differences in the PR (12.8% 48 vs. 6.5% 49 ) were seen when the same test brand (FOB Gold) was applied at an identical threshold (10 mg Hb/ g feces). In our study, we could show that the adjustment of the threshold value to yield a certain PR would have led to almost identical specificities and a much narrower range of sensitivities. In screening practice, instead of simply applying and strictly sticking to the threshold value recommended by the manufacturer the advantage of quantitative FITs regarding the flexibility for threshold adjustments should be extensively exploited to adjust the threshold value to yield a desired PR (which is a very good proxy indicator for the specificity). The PR reflects the colonoscopy workload, which is a limiting factor in many countries, and can be determined in a very straightforward manner without a need for a follow-up of the participants. Such a threshold adjustment has recently been made, for example, in the FIT-based screening program of the Netherlands, where the initial threshold of 15 mg Hb/g feces of FOB Gold was later increased to 47 mg Hb/g feces. 15 Although the diagnostic performance of FITs has been reviewed previously, our study expands evidence on this important issue in several respects. Lee et al. 17 published a systematic review and meta-analysis of (qualitative and quantitative) FITs, with the use of two different reference standards (colonoscopy and occurrence of CRC within two years of follow-up). However, this review included studies published until 2013 and considered only the diagnostic performance of CRC at only one threshold value. Robertson We could extract additional nonreported sensitivities and specificities for CRC, AA and AN as well as PRs of the original articles which were never published before. In addition, we reported data regarding the sample collection method and the storage temperature until the day of evaluation. We performed a meta-analysis by plotting summary ROC curves and computing the corresponding AUCs for the detection of CRC, AA and AN, respectively, and assessed the correlation between thresholds, PRs, sensitivities and specificities, which provide important clues as to the interpretation of the apparent heterogeneity of FIT performance and ways to deal with this heterogeneity in further research and practice. Our review has several strengths and limitations. Although we conducted a systematic literature search in two established databases along with intensive crossreferencing, we cannot guarantee that we have found every relevant article. For example, language bias might have occurred because our search was limited to English and German articles. Besides, overestimated summary results of diagnostic performance due to publication bias cannot be ruled out. Strengths include strict adherence to the PRISMA guidelines and inclusion of comprehensive assessment of studies' quality. We recomputed all sensitivity and specificity values of all the included articles to unify the statistical methods among them.
Despite its limitations, our study provides important information regarding the diagnostic performance of different quantitative FIT brands. Quantitative FITs have an excellent potential to detect most CRCs at high levels of specificity. The apparent large heterogeneity in diagnostic performance between tests can be almost completely overcome by appropriate threshold adjustments. In screening practice, the threshold value should be adjusted to yield a desired PR which is a very good proxy indicator for the specificity and reflects the colonoscopy workload, instead of simply applying and strictly sticking to the threshold value recommended by the manufacturer. Our review also disclosed the lack of direct, head-to-head comparisons of diagnostic performance of different FITs. To evaluate potential differences in diagnostic performance of a rising number of quantitative laboratory-based and point-of-care 51, 52 FITs entering the market, a head-to-head comparison within a single screening study, using identical fecal samples and conducted under equal pre-analytical conditions would be highly desirable.
